F 12198

Drug Profile

F 12198

Latest Information Update: 15 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Antihyperlipidaemics
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atherosclerosis

Most Recent Events

  • 15 Nov 2005 No development reported - Preclinical for Atherosclerosis in France (unspecified route)
  • 21 Nov 2002 bioMérieux - Pierre Fabre Group has demerged
  • 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top